

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection

Stefania Fiorcari,^{1} Claudio Giacinto Atene,^{1*} Rossana Maffei,² Giulia Debbia,¹ Leonardo Potenza,^{1,2} Mario Luppi^{1,2} and Roberto Marasca^{1,2}*

¹Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena and ²Hematology Unit, Department of Oncology and Hematology, A.O.U of Modena, Policlinico, Modena, Italy

**SF and CGA contribute equally as co-first authors.*


Correspondence:

STEFANIA FIORCARI - stefania.fiorcari@unimore.it

ROBERTO MARASCA - roberto.marasca@unimore.it


doi:10.3324/haematol.2020.277392

Supplementary Figure legends



Supplementary Figure S1

Supplementary Figure S1. Scatter plots exemplify the secretion of TNF-α and IFN-γ by CD3+ and CD14+ cells after stimulation with SARS-CoV-2 peptides either in presence or absence of pre-treatment with ibrutinib in one representative CLL sample.



Supplementary Figure S2

Supplementary Figure S2. Scatter plots exemplify the secretion of TNF- α and IFN- γ by CD3+ and CD14+ cells after stimulation with SARS-CoV-2 peptides pre-treatment and after 3 months of treatment with ibrutinib in one representative CLL sample.